Out-of-Specification Sample-Size Confusion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Out-of-Specification Sample-Size Confusion
Precedents set in the historic Barr case continue to raise questions over suitable sample-size criteria.


Pharmaceutical Technology
pp. 28, 54


Lynn D. Torbeck
The sample size needed to investigate an out-of-specification (OOS) result continues to be a point of contention within the pharmaceutical industry. The following quotes from the US vs. Barr Laboratories case, which covered OOS issues, provide good background to the discussion (1):

"... the number of retests performed before a firm concludes that an unexplained out of specification result is invalid or that a product is unacceptable is a matter of scientific judgment."

"Nevertheless, retesting cannot continue ad infinitum. Because such a practice is not scientifically valid ..."

"Such a conclusion cannot be based on 3 of 4 or 5 of 6 passing results, but possibly 7 of 8."

" ... retesting determinations will vary on a case by case basis, a necessary corollary of which is that an inflexible retesting rule, designed to be applied in every circumstance, is inappropriate."

The specific question here is: "How big should the sample be?" and it is the most commonly asked question of a professional statistician. The truth is that there is no simple answer because it depends on the information available. There are at least four possible approaches:

  • Scientific estimate
  • Seven out of eight as in the Barr case
  • Statistical formula with historical estimates
  • Statistical formula with sample.

Scientific estimate

One approach to determine the sample size would be to ask a trained analyst with industry experience to use his or her best scientific judgment to determine what would be an adequate sample size to select. Prior to the Barr case this was (and still is in some places) the standard operating procedure. Although this has scientific basis in the fact that the best person available uses all information to estimate a size, the fact that different people would not get the same number is not scientific. However, the Barr case quotes would seem to support this approach.

Seven out of eight

As in the Barr case, the seven out of eight rule is used by some companies in the absence of any other available information. However, so far there is little statistical justification for seven versus any other value. Some companies choose nine only so they can say they have improved upon the Barr criteria.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here